View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 22, 2021updated 11 Jul 2022 3:10pm

Oravax to commence trials of oral Covid-19 vaccine in Israel

The VLP vaccine addresses three surface proteins of SARS CoV-2, which could allow its efficacy against viral variants.

Oramed Pharmaceuticals’s Oravax is set to initiate clinical trials of its oral Covid-19 vaccine in Israel with the study protocol approved by the Institutional Review Board (IRB) at Ichilov Hospital in the country.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company is currently awaiting approval from the Israeli Ministry of Health for the trial.

Oravax leverages Oramed’s protein oral delivery (POD) technology to develop an oral version of vaccines that are currently available only via injection.

The virus-like particle (VLP) vaccine technology of Oravax acts on three surface proteins of the SARS CoV-2 virus, including proteins that are less prone to mutation. This could potentially enable the vaccine’s efficacy against existing and future viral variants.

Additionally, the VLP platform technology can be administered as an injection or orally.

Oravax is developing the oral VLP Covid-19 vaccine for use as a standalone vaccine and a booster for individuals who have already received Covid-19 vaccines.

The company noted that specialists, including at the World Health Organization (WHO), anticipate that booster doses will be required for the general population and those who are at risk.

Oravax intends to expand the Israeli clinical trial of the vaccine to global study centres. The vaccine is also being analysed in preclinical trials against Covid-19 variants including the Delta variant.

The GMP production for the vaccine is currently progressing.

Oramed Pharmaceuticals CEO Nadav Kidron said: “Our vaccine is a particularly strong candidate against the evolving Covid-19 virus due to its unique targeting of three proteins rather than one.

“With the Delta and other variants proving a challenge to health administrators globally, Oravax’s VLP technology could prove even more important in the effort to combat Covid.”

Furthermore, Oravax out-licensed specific rights to its VLP technology to an Indian firm, Premas Biotech, to develop and market injectable form of the technology in India.

As part of the deal, Oravax is eligible to get royalty payments from Premas upon marketing the injectable vaccine in India.

Kidron added: “Because Oravax is focused on oral vaccines, we saw a clear benefit to out-licensing rights to the injectable version in India, where there is an urgent need for vaccines.”

Premas intends to produce, evaluate and potentially market the injectable vaccine in India where the Covid-19 vaccine market is expected to grow to more than $2.3bn by 2027.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena